Evidence map›Paper›PMID 25897260›Full record

ReviewIntegrated blood pressure control2015

Vitamin D status and hypertension: a review.

Liang Ke, Rebecca S Mason, Maina Kariuki, Elias Mpofu, Kaye E Brock

Open access · goldAbstract readReview
In one paragraph

Review in Integrated blood pressure control, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Vitamin D improves hepatic alterations inSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  10. Latest Knowledge on the Role of Vitamin D in Hypertension.International journal of molecular sciences · 2023
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Vitamin D and Arterial Hypertension: Facts and Myths.Current hypertension reports · 2020
    Review
  16. Article
  17. Association of serum 25-hydroxyvitamin D levels with primary hypertension: a study from south India.Hypertension research : official journal of the Japanese Society of Hypertension · 2020
    Article
  18. Article
  19. Vitamin D and cardiovascular disease in chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Liang KeFaculty of Health Sciences, University of Sydney, Sydney, NSW, Australia.
Rebecca S MasonFaculty of Medicine, University of Sydney, Sydney, NSW, Australia.
Maina KariukiBiostatistical Officer Training Program, NSW Ministry of Health, Sydney, NSW, Australia.
Elias MpofuFaculty of Health Sciences, University of Sydney, Sydney, NSW, Australia.
Kaye E BrockFaculty of Medicine, University of Sydney, Sydney, NSW, Australia.
University of Sydney · AUNew South Wales Department of Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D is a steroid prohormone synthesized in the skin following ultraviolet exposure and also achieved through supplemental or dietary intake. While there is strong evidence for its role in maintaining bone and muscle health, there has been recent debate regarding the role of vitamin D deficiency in hypertension based on conflicting epidemiological evidence. Thus, we conducted a scoping systematic literature review and meta-analysis of all observational studies published up to early 2014 in order to map trends in the evidence of this association. Mixed-effect meta-analysis was performed to pool risk estimates from ten prospective studies (n=58,262) (pooled risk for incident hypertension, relative risk [RR] =0.76 (0.63-0.90) for top vs bottom category of 25-hydroxyvitamin D [25OHD]) and from 19 cross-sectional studies (n=90,535) (odds ratio [OR] =0.79 (0.73-0.87)). Findings suggest that the better the assessed quality of the respective study design, the stronger the relationship between higher 25OHD levels and hypertension risk (RR =0.67 (0.51-0.88); OR =0.77 (0.72-0.89)). There was significant heterogeneity among the findings for both prospective and cross-sectional studies, but no evidence of publication bias was shown. There was no increased risk of hypertension when the participants were of older age or when they were vitamin D deficient. Younger females showed strong associations between high 25OHD levels and hypertension risk, especially in prospective studies (RR =0.36 (0.18-0.72); OR =0.62 (0.44-0.87)). Despite the accumulating evidence of a consistent link between vitamin D and blood pressure, these data are observational, so questions still remain in relation to the causality of this relationship. Further studies either combining existing raw data from available cohort studies or conducting further Mendelian analyses are needed to determine whether this represents a causal association. Large randomized controlled trials are also needed to determine whether vitamin supplementation may be beneficial in the prevention or the treatment of hypertension.

Indexed as

25OHDblood pressurecross-sectionalhigh blood pressuremeta-analysisprospective

Identifiers

PMID25897260
PMCPMC4396645
OpenAlexW1972466609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.